Diabetes results from a complex series of abnormalities in insulin function and/or insulin secretion. As a result abnormally high blood sugar levels may occur with subsequent significant and severe cardiovascular complications arising in some individuals.

Aus Bio has to date identified two lead candidates. Furthermore oral bio availability studies and PK studies in animals have been completed with results suggesting once weekly oral administration may be possible.

In vitro studies have strongly suggested that MD 960 has an insulin sensitizing action acting as a protein tyrosine phosphatase inhibitor. This proposed Mode of Action would help to explain the reproducible blood glucose lowering effect that has been demonstrated in a diabetic animal model.

Some Features.

• Normalizes blood glucose levels.
• No abnormally low blood glucose levels in diabetic animal models.
• Significant Toxicology/Safety data accumulated.
• Beneficial cardiovascular effects identified.
• Suitable for pharmaceutical scale-up.
• Patent coverage includes US, Thailand, Russia, etc.